Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIIT-CD: Intensive Ustekinumab Induction in Crohn's Disease
NCT05861167Phase 4Unknown
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ustekinumab in Crohn's disease (2 arms), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoint: Clinical Response Rate at 24 weeks. Status: unknown.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05861167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861167.